October 25, 2018 — IBA announced the first irradiation of a Spot Scanning Proton Arc (SPArc) plan at the Beaumont Health Proton Therapy Center in Royal Oak, Mich., on its single-room proton therapy solution Proteus One.
Proton arc therapy has the possibility to further improve the quality of the treatment by enhancing the dose conformity at the tumor level while reducing the total dose received by the patient. In addition, the Spot-Scanning Proton Arc therapy technique potentially increases the robustness of the treatment plan and may further improve the adoption of dose escalation and hypofractionation. This first irradiation achieved is the result of a long-standing research and development program between IBA and Beaumont Health’s proton therapy team.
Craig Stevens, M.D., Ph.D., chairman, radiation oncology, Beaumont Health, commented: “Beaumont Health has been leading the research in radiotherapy for decades and we have been working closely on this innovative project with IBA. Combining our expertise will bring patient treatment using proton therapy to the next level. Proton arc therapy has been contemplated for some time. The recent improvements in beam quality and delivery are enabling us to develop a clinically viable product. Spot-Scanning Proton Arc (SPArc) therapy has the potential to allow proton therapy practitioners to improve dose conformity at the tumor while further reducing dose to surrounding healthy tissue and increasing treatment effectiveness.”
See an example of proton arc therapy in the VIDEO "Beaumont's Experience With Proton Therapy After One Year" — interview with Peyman Kabolizadeh, M.D., medical director, Beaumont Proton Therapy Center.
For more information: www.iba-worldwide.com
April 21, 2025 
